Lista de obras - Alessandro Russo - Dominio Público Uruguay

A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection

scientific article published on 07 March 2020

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

artículo científico publicado en 2015

Acquired resistance in oncogene-addicted non-small-cell lung cancer

artículo científico publicado en 2018

Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

artículo científico publicado en 2018

Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario

scientific article published on 22 July 2019

Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]

artículo científico publicado en 2020

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

artículo científico publicado en 2018

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

artículo científico publicado en 2015

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

artículo científico publicado en 2017

Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

artículo científico publicado en 2022

HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target

artículo científico publicado en 2020

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario ⬇️

article

How I treat ALK-positive non-small cell lung cancer

artículo científico publicado en 2019

Immunotherapy in Lung Cancer: From a Minor God to the Olympus

artículo científico publicado en 2020

Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study

artículo científico publicado en 2019

Liquid biopsy for early stage lung cancer moves ever closer

artículo científico publicado en 2020

Liquid biopsy tracking of lung tumor evolutions over time

scientific article published on 16 October 2019

Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

artículo científico publicado en 2016

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

scientific article published on 24 January 2020

Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America

artículo científico publicado en 2020

NSCLC and HER2: between lights and shadows

artículo científico

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

artículo científico publicado en 2016

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

scientific article published on 30 January 2020

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

artículo científico publicado en 2020

Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma

artículo científico publicado en 2019

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

scientific article published on 30 April 2020

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

artículo científico publicado en 2020

RET fusions in solid tumors

scientific article published on 30 October 2019

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.

artículo científico publicado en 2017

Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy

artículo científico publicado en 2020

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

artículo científico publicado en 2018

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

artículo científico

Lista de obras de Alessandro Russo

A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Acquired resistance in oncogene-addicted non-small-cell lung cancer

Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario

Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario ⬇️

How I treat ALK-positive non-small cell lung cancer

Immunotherapy in Lung Cancer: From a Minor God to the Olympus

Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study

Liquid biopsy for early stage lung cancer moves ever closer

Liquid biopsy tracking of lung tumor evolutions over time

Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America

NSCLC and HER2: between lights and shadows

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

RET fusions in solid tumors

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.

Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going